Allergy Therapeutics (AGY)

 

Latest News

Allergy Therapeutics to present on 7 March 2018 at the Shares and AJ Bell Spotlight Evening in London

If you are looking for some investment ideas for your ISA, then come along the Shares and AJ Bell Investor Evening in Lo...

Allergy completes recruitment in grass allergy study, results due ahead of expectations

Allergy Therapeutics plc announced Monday that recruitment has been completed in its grass allergy Phase II study with r...

Completion of recruitment in PQ Grass Ph II trial

RNS Number: 5209E Allergy Therapeutics PLC 12 February 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Completion of recruitment in PQ Grass Phase II trial Trial running ahead of schedule with data now due in early H2 2018 12 February 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specia...

Hardman Research: Growth in a tough market

RNS Number: 7100D Allergy Therapeutics PLC 02 February 2018 Hardman Research: Growth in a tough market Growth in a tough market: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in th...

All News

DateHeadlineSource
01-04-15Holding(s) in CompanyRNS
30-03-15Result of General Meeting and Issue of EquityRNS
10-03-15Allergy Therapeutics placing raises £20m StockMarketWire
10-03-15Issue of EquityRNS
02-03-15Allergy Therapeutics revenues up StockMarketWire
02-03-15Half Yearly ReportRNS
30-01-15Holding(s) in CompanyRNS
12-01-15Allergy Therapeutics revenues up 11%StockMarketWire
12-01-15Trading UpdateRNS
16-12-14Allergy Therapeutics appoints adviser StockMarketWire
19-11-14Allergy Therapeutics resolutions passed at AGMStockMarketWire
18-11-14Allergy strengthens its board StockMarketWire
08-10-14Allergy Therapeutics director steps down StockMarketWire
22-09-14Profits improve at Allergy TherapeuticsStockMarketWire
27-08-14Allergy Therapeutics schedules results announcementStockMarketWire
24-07-14Allergy Therapeutics revenues upStockMarketWire
30-04-14Allergy Therapeutics' licence renewedStockMarketWire
17-04-14Allergy Therapeutics convertible loan extendedStockMarketWire
24-03-14Allergy grows profits StockMarketWire
19-02-14Health Canada approves Allergy CTA submission StockMarketWire
27-01-14Allergy Therapeutics study results publishedStockMarketWire
14-01-14Allergy Therapeutics revenues up 12%StockMarketWire
20-11-13Allergy Therapeutics resolutions passed at AGMStockMarketWire
20-11-13Allergy Therapeutics appoints R&D directorStockMarketWire
20-11-13Allergy Therapeutics revenues upStockMarketWire
27-09-13Allergy Therapeutics appoints adviser StockMarketWire
16-09-13Allergy Therapeutics improves market shareStockMarketWire
15-08-13Allergy Therapeutics schedules FY results StockMarketWire
11-03-13Allergy Therapeutics granted US patent StockMarketWire
03-08-12Markets: FTSE 100 climbs higher on FridayInteractive Investor
18-04-12Markets: FTSE 100 uncertain on WednesdayInteractive Investor
06-12-11Markets: FTSE 100 flat on TuesdayInteractive Investor
26-04-11Markets: Manufacturing data lifts FTSE 100Interactive Investor
26-04-11FDA approval lifts shares in Allergy TherapeuticsInteractive Investor
28-03-11Markets: FTSE 100 trims gains on MondayInteractive Investor

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account